Cargando…

Lenvatinib enhances antitumor immunity by promoting the infiltration of TCF1 (+) CD8 (+) T cells in HCC via blocking VEGFR2

Lenvatinib is the favorable treatment for advanced hepatocellular carcinoma (HCC), and it is currently undergoing phase III clinical trials. However, the specific effects of lenvatinib on PD1(+) CD8(+) T cells in HCC microenvironment have not been systematically studied. Here, we established an orth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mei, Zhibin, Gao, Xingxing, Pan, Caixu, Wu, Qinchuan, Wang, Shuai, Qian, Junjie, Xu, Zhentian, Xu, Kangdi, Zhou, Lin, Zhen, Shushen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067412/ https://www.ncbi.nlm.nih.gov/pubmed/36609997 http://dx.doi.org/10.1111/cas.15719

Ejemplares similares

Combination with Toll-like receptor 4 (TLR4) agonist reverses GITR agonism mediated M2 polarization of macrophage in Hepatocellular carcinoma
por: Pan, Caixu, et al.
Publicado: (2022)

Nanosecond Pulsed Electric Field Induces an Antitumor Effect in Triple-Negative Breast Cancer via CXCL9 Axis Dependence in Mice
por: Xu, Zhentian, et al.
Publicado: (2023)

Integrin subunit beta 8 contributes to lenvatinib resistance in HCC
por: Hou, Wei, et al.
Publicado: (2022)

Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage
por: Yamamoto, Yuji, et al.
Publicado: (2014)

Disulfiram/Copper Induces Immunogenic Cell Death and Enhances CD47 Blockade in Hepatocellular Carcinoma
por: Gao, Xingxing, et al.
Publicado: (2022)

SSRP1 Is a Prognostic Biomarker Correlated with CD8(+) T Cell Infiltration in Hepatocellular Carcinoma (HCC)
por: Luo, Guanshui, et al.
Publicado: (2021)

Targeting VEGF/VEGFR to Modulate Antitumor Immunity
por: Yang, Ju, et al.
Publicado: (2018)

Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib
por: Tada, Toshifumi, et al.
Publicado: (2021)

Tumor-infiltrating B cells producing antitumor active immunoglobulins in resected HCC prolong patient survival
por: Brunner, Stefan M., et al.
Publicado: (2017)

IRF2 regulates cellular survival and Lenvatinib-sensitivity of hepatocellular carcinoma (HCC) through regulating β-catenin
por: Guo, Yarong, et al.
Publicado: (2021)

Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells
por: Hou, Fang-jie, et al.
Publicado: (2019)

Lenvatinib Promotes the Antitumor Effect of Doxorubicin in Anaplastic Thyroid Cancer
por: Su, Xi, et al.
Publicado: (2020)

Sophoridine suppresses lenvatinib‐resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression
por: Zhao, Zhongwei, et al.
Publicado: (2020)

M2 macrophage inhibits the antitumor effects of Lenvatinib on intrahepatic cholangiocarcinoma
por: Yang, Long, et al.
Publicado: (2023)

Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports
por: Tian, Yuan, et al.
Publicado: (2023)

SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway: SREBP2 Inhibitor sensitizes HCC to lenvatinib
por: Fan, Minghao, et al.
Publicado: (2023)

Immune-Mediated Antitumor Effect By VEGFR2 Selective Inhibitor For Gastric Cancer
por: Yang, Ju, et al.
Publicado: (2019)

Synergistic Anti-Angiogenic Effect of Combined VEGFR Kinase Inhibitors, Lenvatinib, and Regorafenib: A Therapeutic Potential for Breast Cancer
por: Bajbouj, Khuloud, et al.
Publicado: (2022)

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
por: Kobayashi, Masahiro, et al.
Publicado: (2019)

A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC
por: Lee, Jaejun, et al.
Publicado: (2020)

Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study
por: Fu, Zhigang, et al.
Publicado: (2021)

Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

A novel VEGFR inhibitor ZLF-095 with potent antitumor activity and low toxicity
por: Li, Xiao, et al.
Publicado: (2023)

C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib
por: Hayashi, Tsuguru, et al.
Publicado: (2020)

Efficacy and safety of TACE combined with lenvatinib and PD‐1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study
por: Wang, Wei‐Jun, et al.
Publicado: (2023)

Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus
por: Matsuki, Masahiro, et al.
Publicado: (2017)

Long‐term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion
por: Takeda, Haruhiko, et al.
Publicado: (2019)

Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway
por: Hao, Jianwen, et al.
Publicado: (2021)

Combination of Vitamin C and Lenvatinib potentiates antitumor effects in hepatocellular carcinoma cells in vitro
por: Wang, Xinyue, et al.
Publicado: (2023)

The role of (18)F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy
por: Wang, Guanyun, et al.
Publicado: (2023)

Design, synthesis and biological evaluation of VEGFR-2/HDAC dual inhibitors as multitargeted antitumor agents based on fruquintinib and vorinostat
por: Gao, Yali, et al.
Publicado: (2023)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
por: Kwok, Christopher, et al.
Publicado: (2023)

TM4SF1 upregulates MYH9 to activate the NOTCH pathway to promote cancer stemness and lenvatinib resistance in HCC
por: Yang, Si-bo, et al.
Publicado: (2023)

Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model
por: Kimura, Takayuki, et al.
Publicado: (2018)

Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells
por: Kawamura, Yoshifumi, et al.
Publicado: (2021)

Lenvatinib or anti-VEGF in combination with anti–PD-1 differentially augments antitumor activity in melanoma
por: Tran, Thuy T., et al.
Publicado: (2023)

Corrigendum: The role of 18F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy
por: Wang, Guanyun, et al.
Publicado: (2023)

Tubulin Alpha 1b Is Associated with the Immune Cell Infiltration and the Response of HCC Patients to Immunotherapy
por: Hu, Xinyao, et al.
Publicado: (2022)

KIF14 and KIF23 Promote Cell Proliferation and Chemoresistance in HCC Cells, and Predict Worse Prognosis of Patients with HCC
por: Cheng, Chunxia, et al.
Publicado: (2020)

Synergistic antitumor efficacy of aspirin plus lenvatinib in hepatocellular carcinoma via regulating of diverse signaling pathways
por: Yan, Xijing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u122vk79d0sk4brlac5etl5bl6